Figure 2: uPA and α-SMA immunoreactivity overlap in fibrotic lung tissue of IPF patients.
From: The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF
Sequential serial lung tissue sections from either (a–b) IPF patient (ALF027) or (c–d) control (ALF024) stained for (a,c) uPA or (b,d) α-smooth muscle actin (α-SMA). The scale bars in images are (a–b) 200 or (c–d) 100 micron.
